Patients with CAN progression were older; had a longer duration of diabetes; used more insulin; and had a higher level of HbA1c, fasting plasma glucose, LDL-cholesterol, and urinary albumin excretion (Table 1). This evidence concerns the gene INS and diabetes mellitus.